MGM Resorts International vs Zoetis Inc — how do they compare? MGM Resorts International trades at $44.5 (market cap $11.10B), while Zoetis Inc trades at $73.7 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 2.8× MGM Resorts International's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| MGM | ZTS | |
|---|---|---|
Market Cap | $11.10B | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $156.76 |
52-Week Low | $30.72 | $71.91 |
Enterprise Value | $38.40B | $38.70B |
Dividend Yield | 0.03% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $43.915, up 1.28% on the day, with a bearish technical signal and neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.59 per share versus $0.63 expected, though revenue hit a record. The company faces a shareholder investigation into Barry Diller's proposed acquisition at $48.30 per share. Fundamentals show a P/E of 26.75 and net income margin of 2.4%, with revenue growth to $17.54B in 2025.
The outlook is mixed: analyst consensus targets $51.14 with 49% buy ratings, but technicals and acquisition uncertainty pose risks. Upside hinges on Las Vegas recovery and BetMGM's iGaming expansion, while margin pressures and legal probes are headwinds. Cash flow trends improved to a projected net positive $572M in 2026, supporting stability.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
Latest headlines on both assets
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →